Ongoing strategic partnership advances joint pipeline in neurodegeneration research•     Evotec receives a $20 million payment to further progress research ...

Triggers a $20 million research payment to Evotec, enabling further development of a preclinical program in neurodegeneration ...

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief ...

EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

This page uses Cookies. For proper functioning of the page Cookies are needed. You agree to using Cookies by clicking "OK". More infos can be found in our Privacy declaration . If you disagree this ...

Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ ...

Evotec SE, the Hamburg-based pharmaceutical research company, is undergoing significant leadership transitions as it navigates through challenging market conditions. The company announced that current ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

EQS-News: EVOTEC SE / Key word (s): Miscellaneous Evotec announces change in Management Board 26.02.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement.

HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long ...